NASDAQ:EVLO

Evelo Biosciences - EVLO Stock Forecast, Price & News

$2.41

+0.15 (+6.64%)

(As of 10/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.15
▼
$2.42
50-Day Range: $1.86
▼
$3.01
52-Week Range: $1.42
▼
$12.74

Volume: 62,393 shs
Average Volume: 277,405 shs
Market Capitalization: $260.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.38

Evelo Biosciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 662.4% Upside
$18.38 Price Target
Short Interest: Bearish
3.72% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.56) to ($1.32) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

721st out of 1,072 stocks

Pharmaceutical Preparations Industry

350th out of 534 stocks

3.4

Analyst's Opinion

Consensus Rating
Evelo Biosciences has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.38, Evelo Biosciences has a forecasted upside of 662.4% from its current price of $2.41.
Amount of Analyst Coverage
Evelo Biosciences has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.72% of the outstanding shares of Evelo Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Evelo Biosciences has a short interest ratio ("days to cover") of 18.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Evelo Biosciences has recently decreased by 0.99%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Evelo Biosciences does not currently pay a dividend.
Dividend Growth
Evelo Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EVLO.

2.7

News and Social Media Coverage

News Sentiment
Evelo Biosciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Evelo Biosciences this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for EVLO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Evelo Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Evelo Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.20% of the stock of Evelo Biosciences is held by insiders.
Percentage Held by Institutions
81.60% of the stock of Evelo Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Evelo Biosciences are expected to grow in the coming year, from ($1.56) to ($1.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Evelo Biosciences is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Evelo Biosciences is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Evelo Biosciences has a P/B Ratio of 15.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Evelo Biosciences (NASDAQ:EVLO) Stock

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVLO Stock News Headlines

September 7, 2022 | finance.yahoo.com

Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress

September 1, 2022 | finance.yahoo.com

Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference

October 6, 2022 | Legacy Research (Affiliate) (Ad)

Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast

He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January… And now, he’s issuing a brand-new warning – along with a unique solution.

August 23, 2022 | nasdaq.com

Insiders of Evelo Biosciences, Inc. (NASDAQ:EVLO) are probably glad they bought last year as their US$575k investment now stands at US$870k

August 22, 2022 | nasdaq.com

Buying the Dip: Here are Top 5 Stocks Hedge Funds Bought the Most

August 16, 2022 | markets.businessinsider.com

Senda Biosciences Announces Close of $123 Million Series C Financing

August 12, 2022 | seekingalpha.com

Evelo Biosciences, Inc. (EVLO) CEO Simba Gill on Q2 2022 Results - Earnings Call Transcript

August 11, 2022 | finance.yahoo.com

Evelo Biosciences, Inc. (EVLO) Q2 2022 Earnings Call Transcript

October 6, 2022 | Tradewins (Ad)

The Safest Option in Trades!

If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

August 11, 2022 | finance.yahoo.com

Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights

August 11, 2022 | marketwatch.com

Evelo Biosciences President, CEO Gill to Transition to Chairman >EVLO

August 11, 2022 | nasdaq.com

Evelo Biosciences Q2 Loss Narrows; Announces CEO Transition

August 10, 2022 | msn.com

Earnings Preview For Evelo Biosciences

August 8, 2022 | finance.yahoo.com

What Type Of Shareholders Own The Most Number of Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?

August 5, 2022 | finance.yahoo.com

Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022

July 18, 2022 | marketwatch.com

Evelo Biosciences Names Marella Thorell as CFO

July 18, 2022 | markets.businessinsider.com

Evelo Biosciences Appoints Marella Thorell As CFO

July 18, 2022 | finance.yahoo.com

Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer

June 24, 2022 | finance.yahoo.com

Bullish Evelo Biosciences, Inc. (NASDAQ:EVLO) insiders were rewarded last week as their US$575k investment inflated to US$799k

June 7, 2022 | markets.businessinsider.com

Cytovia Therapeutics Appoints Luca Scavo as Chief Financial Officer and James Priour as Chief Product Officer

May 25, 2022 | baystreet.ca

Evelo Jumps on Unveiling Direct Offering

May 25, 2022 | seekingalpha.com

Evelo Biosciences agrees over $79.2M direct offering of shares

May 25, 2022 | finance.yahoo.com

Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock

May 12, 2022 | finance.yahoo.com

CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights

May 12, 2022 | finance.yahoo.com

Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights

April 14, 2022 | finance.yahoo.com

Read Why Did Evelo Discontinue EDP1867 Atopic Dermatitis Program

April 14, 2022 | seekingalpha.com

Evelo stock falls as it puts EDP1867 eczema program on hold

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVLO Company Calendar

Last Earnings: 8/11/2022
Today: 10/05/2022
Next Earnings (Estimated): 10/27/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EVLO
CUSIP: N/A
CIK: 1694665
Web: www.evelobio.com
Phone: (617) 577-0300
Fax: N/A
Employees: 122
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.38
High Stock Price Forecast: $41.50
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +662.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-122,180,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -810.73%
Return on Assets: -130.97%

Debt

Debt-to-Equity Ratio: 1.14
Current Ratio: 4.52
Quick Ratio: 4.52

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.16 per share
Price / Book: 15.06

Miscellaneous

Outstanding Shares: 107,994,000
Free Float: 99,138,000
Market Cap: $260.27 million
Optionable: Not Optionable
Beta: 1.45

Key Executives

Dr. Balkrishan Gill Ph.D. (Age 57)
Pres, CEO & Director

Dr. Jonathan B. Zung Ph.D. (Age 57)
Chief Devel. Officer
Comp: $713.28k

Mr. Stephen J. Carriere (Age 67)
VP & Chief Accounting Officer

Dr. Chun Zhang Ph.D.
Chief Technical Operations & Quality Officer

Dr. Mark Bodmer Ph.D. (Age 64)
Chief Scientific Officer and Pres of R&D

Ms. Kendra Sweeney
Head of Investor Relations & Capital Markets

Mr. Daniel S. Char (Age 61)
Gen. Counsel & Sec.

Ms. Jessica Cotrone
VP & Head of Communications

Ms. Leslie Wardwell-Scott Ph.D.
VP and Head of Corp. Devel. & Strategic Integration

Ms. Julie Carretero
Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EVLO Stock - Frequently Asked Questions

Should I buy or sell Evelo Biosciences stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EVLO shares.
View EVLO analyst ratings or view top-rated stocks.
What is Evelo Biosciences' stock price forecast for 2022?: 4 brokerages have issued 1 year target prices for Evelo Biosciences' shares. Their EVLO share price forecasts range from $4.00 to $41.50. On average, they predict the company's share price to reach $18.38 in the next year. This suggests a possible upside of 662.4% from the stock's current price.
View analysts price targets for EVLO or view top-rated stocks among Wall Street analysts.
How have EVLO shares performed in 2022?: Evelo Biosciences' stock was trading at $6.07 at the start of the year. Since then, EVLO stock has decreased by 60.3% and is now trading at $2.41.
View the best growth stocks for 2022 here.
When is Evelo Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our EVLO earnings forecast.
How were Evelo Biosciences' earnings last quarter?: Evelo Biosciences, Inc. (NASDAQ:EVLO) released its quarterly earnings results on Thursday, August, 11th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.16. During the same period in the previous year, the business earned ($0.59) earnings per share.
What other stocks do shareholders of Evelo Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

When did Evelo Biosciences IPO?: (EVLO) raised $85 million in an initial public offering on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.
What is Evelo Biosciences' stock symbol?: Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."
How do I buy shares of Evelo Biosciences?: Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Evelo Biosciences' stock price today?: One share of EVLO stock can currently be purchased for approximately $2.41.
How much money does Evelo Biosciences make?: Evelo Biosciences (NASDAQ:EVLO) has a market capitalization of $260.27 million. The company earns $-122,180,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.
How many employees does Evelo Biosciences have?: The company employs 122 workers across the globe.
How can I contact Evelo Biosciences?: Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The official website for the company is www.evelobio.com. The company can be reached via phone at (617) 577-0300 or via email at ir@evelobio.com.

This page (NASDAQ:EVLO) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Evelo Biosciences - EVLO Stock Forecast, Price & News

Evelo Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows